Dr. Amirhossein Goldan's lab focuses on developing advanced imaging technologies for early diagnosis of Alzheimer's disease. They work on a portable, high-resolution PET scanner that improves the detection of tau protein deposits in the brain, which are indicative of Alzheimer's. This innovative approach aims to enhance accessibility to brain imaging and improve the accuracy of Alzheimer's diagnosis.

Dr. Matthew Blake Greenblatt's lab focuses on understanding how specific skeletal stem cells can be harnessed to promote limb regeneration and improve skeletal health. His research aims to discover how these stem cells function in both limb and vertebral regeneration. By studying the mechanisms underlying these processes, his lab hopes to develop innovative therapies for patients suffering from limb loss or spinal disorders.

Dr. Steven Zvi Josefowicz's lab focuses on understanding how a specific histone protein, H3.3, influences the immune system's response to infection and inflammation. They study how varying levels of H3.3 can adjust the activity of genes involved in immune functions, particularly in cells like macrophages and B cells. By exploring these mechanisms, the lab aims to uncover fundamental insights into how immune responses can be finely tuned, which has implications for treating various diseases.

Dr. John P. Moore's lab focuses on understanding how the immune system can effectively combat HIV-1, the virus that causes AIDS. By studying broadly neutralizing antibodies (bNAbs), the lab aims to improve both vaccine strategies and treatments for HIV-1 infection. The research involves innovative methods to analyze antibody behavior and viral interactions to enhance our knowledge of immunity against HIV-1.

Dr. Xin-Yun Huang's lab focuses on understanding the structural and regulatory mechanisms of the atrial natriuretic peptide receptor (ANPR), crucial for cardiovascular health. The research explores how this receptor regulates blood pressure and maintains cardiovascular balance, aiming to uncover insights that can lead to new therapies for heart diseases. By studying the interactions and conformational changes of the receptor, the lab is poised to contribute significantly to both basic science and clinical applications.

Dr. Jeffrey Ketterling's research lab focuses on improving imaging techniques to study heart diseases in mice. By developing advanced ultrasound technology, the lab aims to detect early signs of heart dysfunction before visible changes occur. This work is crucial for understanding how blood flow patterns affect heart health and could lead to better treatment approaches for patients suffering from heart disease.

Dr. Subhash C. Sinha's lab focuses on discovering new treatments for Alzheimer's disease by targeting the immune system's response to tau pathology, a key factor in memory loss. The research aims to develop small molecule inhibitors of a protein called cGAS, which plays a role in neuroinflammation associated with Alzheimer's. By investigating these inhibitors, the lab hopes to identify therapeutic strategies that can reduce cognitive deficits in Alzheimer's disease.

Dr. Gang Lin's research lab focuses on developing innovative proteasome inhibitors to treat aggressive cancers like triple negative breast cancer and to combat drug-resistant malaria. By understanding protein degradation mechanisms in cells, his team aims to create safer and more effective therapeutics that can address significant health challenges in both oncology and infectious diseases.

David Eliezer's research lab at Weill Medical College focuses on the intriguing role of intrinsically disordered proteins (IDPs) in cell biology, particularly in how they interact with cellular membranes and contribute to important processes such as membrane trafficking and organization. The lab seeks to understand how these dynamic proteins achieve their functions despite lacking a stable structure, with implications in areas like neuron signaling and the formation of membraneless organelles. By studying specific protein models, the lab aims to shed light on the mechanisms that govern cellular organization and communication.

Dr. Ekta Khurana's lab at Weill Medical College focuses on understanding how specific regions of the genome that do not code for proteins can influence the initiation and growth of breast cancer. Using a combination of computational techniques and experimental approaches, the lab aims to identify and manipulate these non-coding genomic elements, particularly in the context of treatment resistance. This research is significant because it may lead to new strategies for cancer treatment by targeting non-coding regions that affect tumor growth.

The lab led by Dr. Ashley Marie Laughney investigates how certain proteins influence cancer development and progression, particularly focusing on the STING protein and chromosomal instability in tumor cells. By developing a new technology called SatSeq, the research aims to map how changes in these proteins affect cancer behavior and responses to therapy. The lab also strives to understand the interactions between cancer cells and their surrounding environment, which can impact the progression and spread of different cancer types.

Dr. Laura Beth Johnson Mcintire's lab focuses on understanding how lipid metabolism changes in the brain due to Alzheimer's disease. They aim to create a detailed atlas of lipid distribution in the brain to help identify key changes that could lead to new biomarkers or therapeutic targets for Alzheimer's. By studying both human brains and mouse models, the lab seeks to connect findings in lipid dysregulation to cognitive decline and disease progression in Alzheimer's disease.

Dr. Wenjie Luo's lab focuses on understanding the role of microglia and cholesterol metabolism in Alzheimer's disease, particularly how a specific gene variant (APOE4) affects neuroinflammation and tau toxicity. The research aims to uncover novel cellular mechanisms and therapeutic targets by studying a cholesterol-related enzyme, CH25H, and its impact on Alzheimer’s progression. This work could lead to new prevention strategies or treatments for Alzheimer's disease.

Dr. Jonathan Mamou's lab focuses on improving the detection and evaluation of lymph nodes, particularly in determining whether they harbor metastatic cancer. By leveraging advanced quantitative ultrasound techniques, his research aims to create better diagnostic tools that can differentiate between cancerous and benign conditions in lymph nodes during routine medical procedures. This work not only seeks to enhance cancer staging but also to facilitate more appropriate treatment strategies for patients.

Dr. Xiaojing Ma's research lab at Weill Medical College focuses on understanding the role of a gene called UBR5 in cancer, particularly breast and ovarian cancer. By studying how UBR5 affects tumor growth and immune response, the lab aims to uncover new therapeutic strategies that could help treat aggressive types of breast cancer that resist current treatments. The findings from this research could significantly improve patient outcomes by targeting specific biological processes that drive cancer progression.

Dr. Paul K. Maciejewski's lab focuses on improving end-of-life care for patients with advanced cancer by addressing their spiritual needs. The lab investigates how integrating healthcare chaplains and faith community support can enhance patients' spiritual wellness and ultimately lead to better decision-making and care at the end of life. By conducting controlled trials and qualitative interviews, the lab seeks to understand the impact of spiritual care on patients' experiences in oncology settings.

Dr. Giovanni Manfredi's lab focuses on understanding how mitochondrial dysfunction contributes to neurological diseases, including conditions like Alzheimer's and Parkinson's. They explore the complex roles mitochondria play in cellular metabolism and how stress responses are activated when mitochondrial function is impaired. This research aims to develop new therapeutic strategies to combat mitochondrial disorders and their effects on the central nervous system.

Dr. Timothy McGraw's lab focuses on understanding how incretin hormones, specifically GIP and GLP-1, control metabolism in the body. These hormones are important for regulating insulin secretion and sensitivity, with potential applications in treating diabetes, heart disease, and even neurodegenerative disorders. The lab develops mouse models to explore the molecular mechanisms of GIP receptor signaling, which could lead to improved therapies targeting these hormones.

Dr. Teresa A Milner's lab focuses on understanding how menopause affects blood pressure and the brain's mechanisms behind this change using mouse models. They specifically look at hormonal changes associated with menopause and how they influence hypertension, particularly through brain signaling pathways. By exploring the roles of estrogen receptors and synaptic plasticity in the hypothalamus, the lab aims to uncover potential new therapies to manage hypertension in postmenopausal women.

Dr. Bobak Mosadegh's lab focuses on improving the care of dialysis patients by using artificial intelligence to screen for problems in their blood vessels. Specifically, they are working on a technology that listens to sounds from a digital stethoscope to detect issues like stenosis in arteriovenous fistulas, which are critical for providing dialysis. By validating this AI tool against traditional imaging methods, the goal is to enhance patient outcomes and reduce unnecessary interventions.